In secondary stroke prevention the Factor Xi inhibitor Asundexian reduced the risk of recurrent ischemic stroke at 1 year by 26%. The absolute reduction was such that only 53 people would we need to be treated to prevent another stroke at 1 year.

There was no increase in mild or severe bleeding or intracranial bleeding

63% of people were on DAPT at study start, and they had the same benefit as people on antiplatelet monotherapy

Similar benefit in medium to large vessel ischemic stroke, lacunar stroke and stroke of unidentified origin

All benefit with no increase in bleeding risk

26-02-02_ISC_OCEANIC-STROKE primary Download

Disclosures: TBD